"Satellite office of Neurology Diagnostics. Mail/ fax/ communications should be directed to Elmwood office."

During the past decade, Neurology Diagnostics Inc. conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 18 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 12 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Neurology Diagnostics Inc." #1 sponsor was "Eli Lilly and Company" with 10 trials, followed by "Pfizer" with 4 trials sponsored, "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 3 trials sponsored, "Opexa Therapeutics, Inc." with 3 trials sponsored and "Athira Pharma" with 3 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Neurology Diagnostics Inc." #1 collaborator was "Pfizer" with 3 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Grifols Biologicals, LLC" with 1 trials as a collaborator, "Immune Tolerance Network (ITN)" with 1 trials as a collaborator and "Premier Research Group plc" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Neurology Diagnostics Inc." are "Alzheimer Disease" (10 trials), "Alzheimer's Disease" (9 trials), "Multiple Sclerosis, Relapsing-Remitting" (5 trials), "Migraine" (3 trials) and "Migraine, With or Without Aura" (3 trials). Many other conditions were trialed in "Neurology Diagnostics Inc." in a lesser frequency.

Most popular intervention types in "Neurology Diagnostics Inc." are "Drug" (39 trials), "Biological" (6 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (24 trials), "Rimegepant" (5 trials), "Donanemab" (4 trials), "ATH-1017" (2 trials) and "Bapineuzumab 0.5 mg/kg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Neurology Diagnostics Inc." are 45 trials for "All" genders.

Currently, there are NaN active trials in "Neurology Diagnostics Inc.". undefined are not yet recruiting, 5 are recruiting, 7 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 25 completed trials in Neurology Diagnostics Inc., undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Neurology Diagnostics Inc., 0 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".